Fact Source: Financial Supervisory Service DART / 2025-04-28
Disclosure Type: Execution of Single Sales/Supply Contract
💡 3-Second Summary
SAMSUNG BIOLOGICS has signed a massive contract manufacturing organization (CMO) agreement worth approximately KRW 737.3 billion with a U.S.-based pharmaceutical firm, representing a substantial 16.21% of its total revenue from the previous fiscal year.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Contract Name: Contract Manufacturing Agreement for Pharmaceuticals
- Contract Amount: KRW 737,326,729,080 (Confirmed amount: USD 513,959,800)
- Applied Exchange Rate: The initial base rate of USD/KRW 1,434.60 as of April 28, 2025.
- Ratio to Recent Revenue: 16.21% (Recent annual revenue based on 2024 consolidated financial statements: KRW 4,547,322,176,421)
- Counterparty: A pharmaceutical company located in the United States (Identity withheld until December 31, 2031, due to operational confidentiality).
- Contract Period: From April 28, 2025, to December 31, 2031 (Approximately 6 years and 8 months).
- Key Terms: No down payment or advance payment is provided (None).
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This supply contract serves as a critical performance indicator reinforcing SAMSUNG BIOLOGICS’ fundamental strength and global competitiveness in the CDMO landscape. Securing a reliable long-term backlog equivalent to over 16% of the previous year’s total sales in a single transaction notably enhances the company’s mid-to-long-term revenue visibility.
Investors should pay close attention to the contract duration, FX exposure, and confidentiality clause. Given that the timeline extends over 6 years through 2031, revenue will likely be recognized progressively according to production schedules rather than in a short-term spike. Furthermore, since the underlying contract is locked in USD (approx. USD 513M), the final KRW-converted top-line metrics could fluctuate depending on macro exchange rate dynamics over time.
While the specific product types or catalysts driving this order are not explicitly detailed in the filing, withholding the counterparty’s identity is standard industry protocol to safeguard competitive strategies and presents no regulatory or structural risks. Continued order momentum from the U.S. market—the global epicenter of major pharmaceutical clients—remains a powerful pillar supporting market confidence.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has landed yet another massive contract in the U.S. market, flexing its operational muscles by locking in a backlog worth over 16% of last year’s total revenue. Securing a USD-denominated contract when the USD/KRW rate stands at a favorable 1,434.60 provides a supportive tailwind for FX-translated earnings conversion.
While the client’s identity remains a mystery until 2031 under a strict confidentiality clause, this is a routine practice among global Big Pharma players seeking to shield proprietary manufacturing pipelines. Although this backlog will translate into progressive revenue recognition across multiple years rather than an instant earnings burst next quarter, it ensures high plant utilization rates and secures a long-term cash flow buffer that global institutional investors highly favor.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
